Commentary
Video
Author(s):
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC
Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma
Park and Grivas Expand on Treatment Updates in Bladder Cancer
Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC
OncLive’s August Roundup of Key FDA Approvals in Oncology
Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC
Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC
Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC
Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status